Frequently asked questions
In 2022, the global Fetal Bovine Serum Market is expected to be worth USD 849.8 million.
The Fetal Bovine Serum Market is estimated to increase at a CAGR of 5.60% between 2023 and 2030, reaching USD 1314.0Million in 2030.
Pharmaceuticals lead the fetal bovine serum market revenue in 2022 and are predicted to be the fastest-growing segment during the forecast period, 2022-2030.
In 2022, the cell culture media sector will lead the fetal bovine serum market growth.
In 2022, the Premium sector has the highest CAGR.
North America will account for 45.8% of total revenue in the fetal bovine serum market in 2022.
The top players include Danaher (Cytiva), Merck KGaA (Sigma Aldrich), HiMedia Laboratories Pvt. Ltd, Bio-Techne, Sera Scandia (Biowest), Sartorius (Biological Industries), Atlas Biologicals, Rocky Mountain Biologicals, PAN-Biotech and Others.
Rising need for regenerative medicine and stem cell research, expanding biotechnology and pharmaceutical sectors, and innovations in cell culture techniques are the key drivers of the market.
Market constraints include concerns regarding the collection of fetal bovine serum, rigorous norms and restrictions controlling its usage, the high cost of fetal bovine serum, and the availability of alternative serum products.
Demand is being driven by the expansion of fetal bovine serum uses in research and diagnostics, developments in cell culture techniques, and rising knowledge of the benefits of fetal bovine serum in cell culture.